Efectos sobre el tejido adiposo : GIP parece tener efectos ms pronunciados sobre el metabolismo de las grasas y el tejido adiposo
Am J Physiol Endocrinol Metab 278: E1010-1018, 2000
This review by Oliver Philps provides an overview of GLP-1 agonists and where they fit in the treatment of diabetes, how the peptide drugs evolved over time to todays weight loss medications, and what to expect next...
Produced by osteoblasts and released into circulationparticularly in its undercarboxylated formosteocalcin has been shown in animal models to enhance insulin secretion, improve insulin sensitivity, increase energy expenditure, and stimulate testosterone production ( Mechanistically, osteocalcin signaling has been linked to the G proteincoupled receptor GPRC6A, providing a plausible pathway through which bone-derived signals influence pancreatic -cells, adipocytes, and Leydig cells
GLP-1 medications can change how the body experiences hunger and fullness